Leggio and his colleagues noted that, compared with other GLP-1 receptor agonists, semaglutide is more potent, has a higher affinity for its receptor, and is longer acting
For someone at high cardiovascular risk, thats often an acceptable tradeoff
[DOI] [PubMed] [Google Scholar] 17.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D.S., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
383 However, the development of CETP inhibitors has faced numerous setbacks, 448,449 with several high-profile drug candidates, such as torcetrapib, dalcetrapib, and evacetrapib, failing in phase III clinical trials owing to either a lack of efficacy or off-target adverse effects
People with cardiovascular concerns or high blood pressure need careful screening before using it